REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information. The claims have been amended to place them in form appropriate to US practice and to reduce the filing fee by removing multiple dependency. Claims 1, 3, 4, and 5 have been amended to parallel the amended claims as indicated in the PCT International Preliminary Examination Report. Claims 11 and 16-21 have been deleted. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted;

Date: March 14, 2001

By: Karen L. Prus

Karen L. PRUS
Attorney of Record, Reg. No 39,337

Glaxo Wellcome Inc.
Global Intellectual Property Department
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-3323
Fax: 919-483-7988

Version With Markings to Show Changes Made to Claims

Claim 1 (Amended in IPER) A combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent [selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and] bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.

Claim 2 A combination according to claim 1 wherein the ratio is in the range 25:1 to 15:1 by weight of active ingredients.

Claim 3 (Amended here and in IPER) A combination according to [any one of] claim[s] 1 [or 3] for use in medicine.

Claim 4 (Amended here and in IPER) A pharmaceutical formulation comprising a combination according to [any one of] claim[s] 1 [to 3] in association with one or more pharmaceutically acceptable carriers therefor.

Claim 5 (Amended in IPER) A pharmaceutical formulation for use in the treatment of HBV comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-[R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.

Claim 6. (Amended here and in IPER) A formulation according to claim[s] 4 [or 5] in unit dosage form.

Claim 7. (Amended here and in IPER) A formulation according to [any one of] claim[s] 5 [to 6] suitable for oral administration.

Claim 8. (Amended) A formulation according to [any one of] claim[s] 5 [to 7] comprising between 25 to 150 mg of lamivudine and 5 to 60 mg adefovir dipivoxil.

Claim 9. A formulation according to claim 8 comprising 100 mg of lamivudine and 10 mg adefovir dipivoxil.

Claim 10. A method for the treatment of a mammal, including a human, with an HBV infection comprising administration of a therapeutically effective amount of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof.

Claim 11 (Deleted)

Claim 12. (Amended) A method according to claim 10 [or claim 11] wherein the combination is administered simultaneously.

Claim 13. (Amended) A method according to claim 10 [or claim 11] wherein the combination is administered sequentially.

Claim 14. (Amended) A method according to claim 10 [or claim 11] wherein the combination is administered as a single combined formulation.

Claim 15. (Amended) A method as claimed in [any one of] claim[s] 10 [to 14] for the treatment of an HBV infection resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus

Claim 16 (Deleted)

Claim 17 (Deleted)

Claim 18 (Deleted)

Claim 19 (Deleted)

Claim 20 (Deleted)

Claim 21 (Deleted)

Claim 22. (Amended in IPER) A patient pack comprising of at least one active ingredient selected from (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one, and bis(pivaloyloxymethyl)(9-[2-(phosphonomethoxy)ethyl]adenine and an information insert containing directions on the use of both active ingredients together in combination.